Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-4489

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-4489). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904489)

Losartan Potassium 50 mg film coated tablets in a carton from A-S Medication Solutions. The label includes product and lot numbers, storage instructions at 68 to 77 degrees Fahrenheit away from light, and states that each film coated tablet contains 50 mg of Losartan Potassium USP. The package contains 30 tablets with the NDC 50090-4489-0.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period for Losartan Potassium and Atenolol. The graph shows two lines, one solid representing Losartan Potassium and one dotted for Atenolol, with an adjusted risk reduction of 13%, p=0.021 noted below the x-axis labeled 'Study Month.' The y-axis represents the percentage of patients with primary endpoints, increasing over time.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over 66 study months between Atenolol and Losartan potassium. The x-axis shows study months from 0 to 66, and the y-axis shows percentage of patients from 0 to 8%. Losartan potassium demonstrates a lower percentage throughout the study period, with an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A data table titled 'Primary Endpoint Events within Demographic Subgroups' comparing event rates and hazard ratios for Losartan Potassium and Atenolol across multiple subgroups. It displays primary composite and stroke (fatal/non-fatal) event rates (%) with hazard ratios (95% CI) for groups by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). The table includes graphics representing hazard ratios favoring Losartan Potassium or Atenolol.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients experiencing an event over 48 months for Losartan Potassium versus placebo. The x-axis represents time in months, and the y-axis shows the percentage of patients with the event. The graph indicates a risk reduction of 16.1% for Losartan Potassium compared to placebo with a p-value of 0.022.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium, the active ingredient in the drug. The diagram shows the molecular arrangement, including a chlorinated imidazole, biphenyl, and tetrazole potassium salt groups, representing the compound's detailed chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.